AAAAAA

   
Results: 1-17 |
Results: 17
Lattice Boltzmann equation hydrodynamics - art. no. 011208
Authors: Halliday, I Hammond, LA Care, CM Good, K Stevens, A
Citation: I. Halliday et al., Lattice Boltzmann equation hydrodynamics - art. no. 011208, PHYS REV E, 6401(1), 2001, pp. 1208
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks
Authors: Rothenberg, ML Kuhn, JG Schaaf, LJ Rodriguez, GI Eckhardt, SG Villalona-Calero, MA Rinaldi, DA Hammond, LA Hodges, S Sharma, A Elfring, GL Petit, RG Locker, PK Miller, LL von Hoff, DD
Citation: Ml. Rothenberg et al., Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks, ANN ONCOL, 12(11), 2001, pp. 1631-1641
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel
Authors: Hidalgo, M Aylesworth, C Hammond, LA Britten, CD Weiss, G Stephenson, J Schwartz, G Patnaik, A Smith, L Molpus, K Felton, S Gupta, E Ferrante, KJ Tortora, A Sonnichsen, DS Skillings, J Rowinsky, EK
Citation: M. Hidalgo et al., Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel, J CL ONCOL, 19(9), 2001, pp. 2493-2503
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
Authors: Hidalgo, M Siu, LL Nemunaitis, J Rizzo, J Hammond, LA Takimoto, C Eckhardt, SG Tolcher, A Britten, CD Denis, L Ferrante, K Von Hoff, DD Silberman, S Rowinsky, EK
Citation: M. Hidalgo et al., Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies, J CL ONCOL, 19(13), 2001, pp. 3267-3279
Exploring the mechanisms of action of FB642 at the cellular level
Authors: Hammond, LA Davidson, K Lawrence, R Camden, JB Von Hoff, DD Weitman, S Izbicka, E
Citation: La. Hammond et al., Exploring the mechanisms of action of FB642 at the cellular level, J CANC RES, 127(5), 2001, pp. 301-313
Antagonists of retinoic acid receptors (RARs) are potent growth inhibitorsof prostate carcinoma cells
Authors: Hammond, LA Van Krinks, CH Durham, J Tomkins, SE Burnett, RD Jones, EL Chandraratna, RAS Brown, G
Citation: La. Hammond et al., Antagonists of retinoic acid receptors (RARs) are potent growth inhibitorsof prostate carcinoma cells, BR J CANC, 85(3), 2001, pp. 453-462
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model
Authors: Hammond, LA Hilsenbeck, SG Eckhardt, SG Marty, J Mangold, G MacDonald, JR Rowinsky, EK Von Hoff, DD Weitman, S
Citation: La. Hammond et al., Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model, EUR J CANC, 36(18), 2000, pp. 2430-2436
Renal pathological findings in infective endocarditis
Authors: Majumdar, A Chowdhary, S Ferreira, MAS Hammond, LA Howie, AJ Lipkin, GW Littler, WA
Citation: A. Majumdar et al., Renal pathological findings in infective endocarditis, NEPH DIAL T, 15(11), 2000, pp. 1782-1787
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies
Authors: Eckhardt, SG Baker, SD Britten, CD Hidalgo, M Siu, L Hammond, LA Villalona-Calero, MA Felton, S Drengler, R Kuhn, JG Clark, GM Smith, SL MacDonald, JR Smith, C Moczygemba, J Weitman, S Von Hoff, DD Rowinsky, EK
Citation: Sg. Eckhardt et al., Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies, J CL ONCOL, 18(24), 2000, pp. 4086-4097
Phase I and pharmacokinetic study of the differentiating agent vesnarinonein combination with gemcitabine in patients with advanced cancer
Authors: Patnaik, A Rowinsky, EK Tammara, BK Hidalgo, M Drengler, RL Garner, AM Siu, LL Hammond, LA Felton, SA Mallikaarjun, S Von Hoff, DD Eckhardt, SG
Citation: A. Patnaik et al., Phase I and pharmacokinetic study of the differentiating agent vesnarinonein combination with gemcitabine in patients with advanced cancer, J CL ONCOL, 18(23), 2000, pp. 3974-3985
DX-8951f, a hexacyclic camptothecin analog, on a daily times-five schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies
Authors: Rowinsky, EK Johnson, TR Geyer, CE Hammond, LA Eckhardt, SG Drengler, R Smetzer, L Coyle, J Rizzo, J Schwartz, G Tolcher, A Von Hoff, DD De Jager, RL
Citation: Ek. Rowinsky et al., DX-8951f, a hexacyclic camptothecin analog, on a daily times-five schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies, J CL ONCOL, 18(17), 2000, pp. 3151-3163
Phase I and pharmacologic study of PN401 and fluorouracil in patients withadvanced solid malignancies
Authors: Hidalgo, M Villalona-Calero, MA Eckhardt, SG Drengler, RL Rodriguez, G Hammond, LA Diab, SG Weiss, G Garner, AM Campbell, E Davidson, K Louie, A O'Neil, JD von Borstel, R Von Hoff, DD Rowinsky, EK
Citation: M. Hidalgo et al., Phase I and pharmacologic study of PN401 and fluorouracil in patients withadvanced solid malignancies, J CL ONCOL, 18(1), 2000, pp. 167-177
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patientswith solid malignancies
Authors: Rowinsky, EK Humphrey, R Hammond, LA Aylesworth, C Smetzer, L Hidalgo, M Morrow, M Smith, L Garner, A Sorensen, JM Von Hoff, DD Eckhardt, SG
Citation: Ek. Rowinsky et al., Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patientswith solid malignancies, J CL ONCOL, 18(1), 2000, pp. 178-186
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies
Authors: Britten, CD Rowinsky, EK Baker, SD Agarwala, SS Eckardt, JR Barrington, R Diab, SG Hammond, LA Johnson, T Villalona-Calero, M Fraass, U Statkevich, P Von Hoff, DD Eckhardt, SG
Citation: Cd. Britten et al., A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies, CLIN CANC R, 5(7), 1999, pp. 1629-1637
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies
Authors: Hammond, LA Eckardt, JR Baker, SD Eckhardt, SG Dugan, M Forral, K Reidenberg, P Statkevich, P Weiss, GR Rinaldi, DA Von Hoff, DD Rowinsky, EK
Citation: La. Hammond et al., Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies, J CL ONCOL, 17(8), 1999, pp. 2604-2613
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors
Authors: Drengler, RL Kuhn, JG Schaaf, LJ Rodriguez, GI Villalona-Calero, MA Hammond, LA Stephenson, JA Hodges, S Kraynak, MA Staton, BA Elfring, GL Locker, PK Miller, LL Von Hoff, DD Rothenberg, ML
Citation: Rl. Drengler et al., Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors, J CL ONCOL, 17(2), 1999, pp. 685-696
Localized bowel vasculitis - Postoperative cyclophosphamide or not?
Authors: Raza, K Exley, AR Carruthers, DM Buckley, C Hammond, LA Bacon, PA
Citation: K. Raza et al., Localized bowel vasculitis - Postoperative cyclophosphamide or not?, ARTH RHEUM, 42(1), 1999, pp. 182-185
Risultati: 1-17 |